MedPath

9 METERS BIOPHARMA, INC.

9 METERS BIOPHARMA, INC. logo
🇺🇸United States
Ownership
Public
Established
2012-01-01
Employees
10
Market Cap
-
Website
http://9meters.com

Clinical Trials

10

Active:0
Completed:7

Trial Phases

3 Phases

Phase 1:3
Phase 2:6
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials

Phase 2
6 (60.0%)
Phase 1
3 (30.0%)
Phase 3
1 (10.0%)

VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.

Phase 2
Terminated
Conditions
Short Bowel Syndrome
Interventions
First Posted Date
2021-08-04
Last Posted Date
2022-12-20
Lead Sponsor
9 Meters Biopharma, Inc.
Target Recruit Count
12
Registration Number
NCT04988997
Locations
🇺🇸

Research Site, Nashville, Tennessee, United States

Proof of Concept Study in Patients With Short Bowel Syndrome

Phase 1
Conditions
Short Bowel Syndrome
Interventions
First Posted Date
2020-05-08
Last Posted Date
2020-11-20
Lead Sponsor
9 Meters Biopharma, Inc.
Target Recruit Count
12
Registration Number
NCT04379856
Locations
🇺🇸

Research Facility One, Los Angeles, California, United States

Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

Phase 3
Terminated
Conditions
Celiac Disease
Interventions
Drug: Matching Placebo
First Posted Date
2018-06-26
Last Posted Date
2022-07-26
Lead Sponsor
9 Meters Biopharma, Inc.
Target Recruit Count
307
Registration Number
NCT03569007
Locations
🇺🇸

Research Site, Wauwatosa, Wisconsin, United States

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Phase 2
Completed
Conditions
Celiac Disease
Interventions
First Posted Date
2011-07-18
Last Posted Date
2017-09-20
Lead Sponsor
9 Meters Biopharma, Inc.
Target Recruit Count
342
Registration Number
NCT01396213

Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease

Phase 2
Completed
Conditions
Celiac Disease
Interventions
Drug: Placebo
Dietary Supplement: Gluten 900 mg
First Posted Date
2009-04-29
Last Posted Date
2017-09-20
Lead Sponsor
9 Meters Biopharma, Inc.
Target Recruit Count
42
Registration Number
NCT00889473
Locations
🇨🇦

Study Site, Edmonton, Alberta, Canada

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath